A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Valbenazine (INGREZZA)

INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Stu....

First FDA approval2017-10-04
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.02B in CY2024 Part D spend391K claims · 61K beneficiaries · 329 plans surveyed

Lowest NADAC
$259.07/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$275.24
Across all dosage forms in distribution.
Highest NADAC
$283.32
Range is tight.
Plans with PA
1370 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Valbenazine used for?

INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Stu....

Is there a generic for Valbenazine?

Yes. 2 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Valbenazine?

Across 329 Part D plans, Valbenazine averages $275.24/unit (NADAC). Lowest available: $259.07/unit. Highest in distribution: $283.32/unit.

Is Valbenazine on the FDA shortage list?

No. Valbenazine is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.